Baricitinib Curative Repression of HIV-1

"Antiretroviral Therapy (ART): A treatment regimen for HIV infection that uses a combination of antiretroviral drugs to suppress viral replication, reduce HIV-related morbidity, and prevent transmission.~In Step 1, participants will continue their current ART regimen for 26 weeks.~In Step 2, participants will interrupt ART.~In Step 3, participants will restart ART treatment early if they meet the ART restart criteria before the end of Step 2 (24-week maximum). Otherwise, they will resume ART at the end of Step 2."

"Baricitinib is an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2. It reduces cytokine-mediated signaling involved in inflammation and immune activation. Baricitinib is FDA-approved for rheumatoid arthritis (RA), atopic dermatitis, and alopecia areata. It has also been authorized for the treatment of COVID-19 in hospitalized patients.~During Step 1, Baricitinib will be taken at a dose of 2 mg orally daily for 26 weeks.~During Step 2, Baricitinib alone will be continued at a dose of 2 mg orally daily for up to an additional 24 weeks"